Metastatic Merkel cell carcinoma response to nivolumab

BACKGROUND: Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine malignancy with limited treatment options. Several lines of evidence support the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis as a likely contributor to immune evasion in MCC. CASE PRESENTATION: We re...

Descripción completa

Detalles Bibliográficos
Autores principales: Walocko, Frances M., Scheier, Benjamin Y., Harms, Paul W., Fecher, Leslie A., Lao, Christopher D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109712/
https://www.ncbi.nlm.nih.gov/pubmed/27879975
http://dx.doi.org/10.1186/s40425-016-0186-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109712/
https://www.ncbi.nlm.nih.gov/pubmed/27879975
http://dx.doi.org/10.1186/s40425-016-0186-1

Ejemplares similares